Baxter Submits Amended BLA to U.S. FDA for HyQvia for Primary Immunodeficiency

16-12-2013 Business Wire HealthComments (0)


Baxter and Halozyme announced that Baxter has submitted an amended BLA to the FDA to re-initiate review of HyQvia for treatment of adults with primary immunodeficiency.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top